<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784234</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #2020-145</org_study_id>
    <nct_id>NCT04784234</nct_id>
  </id_info>
  <brief_title>Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of GlaucoCetin vs Placebo in Glaucoma Patients With Visual Field Loss.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guardian Health Sciences, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at changes in vision and visual function before and after a six month&#xD;
      trial of a daily medical food called GlaucoCetin, formulated with ingredients to support and&#xD;
      protect the optic nerve cells. Open angle glaucoma patients will be randomized to receive&#xD;
      either a placebo or the medical food for 6 months. We hope to learn if this medical food can&#xD;
      improve the vision of our glaucoma patients and to report the findings obtained to the&#xD;
      general public.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the improvement in vision and visual&#xD;
      function during a 6 month trial of GlaucoCetin versus placebo in patients with open angle&#xD;
      glaucoma. The secondary objective is to evaluate change in quality of life,&#xD;
      electrophysiologic response, and contrast sensitivity.&#xD;
&#xD;
      Procedures involved during participation include review of medical/ocular history, best&#xD;
      corrected visual acuity, multiple Humphrey visual field testing 24-2 and 10-2 , Octopus&#xD;
      G-Top, pattern electroretinogram (PERG), ocular coherence tomography (OCT), ocular coherence&#xD;
      tomography angiography (OCTA), intraocular pressure (IOP), contrast sensitivity testing&#xD;
      (CSV-1000), corneal hysteresis, biomicroscopy, fundus exam, disc photos, and serum testing.&#xD;
&#xD;
      To evaluate quality of life, included in testing is Compressed Assessment of Ability Related&#xD;
      to Vision (CAARV). Responses to multiple surveys regarding vision related quality of life&#xD;
      (GQL-15, Glaucoma Symptom Scale (GSS), National Eye Institute Visual Function Questionnaire&#xD;
      25 (NEI VFQ-25)) and diet (NHANES Dietary Screener) will be captured. Number of daily steps&#xD;
      will be monitored at 2 intervals during the study using pedometers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study aims to enroll 50 patients within each intervention arm (GlaucoCetin vs Placebo). Within the intervention arm there will be one group with Central visual field defects and one group with Peripheral visual field defects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking of GlaucoCetin and identical Placebo was provided by Guardian Health Sciences, Inc. Labeling has been conducted by non-clinical study team personnel in Glaucoma Research Center at Wills Eye Hospital.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Field Mean Deviation</measure>
    <time_frame>3 hour examinations during a 6 month period</time_frame>
    <description>Improvement in visual field mean deviation, measured in decibels, will be compared before, during and after a 6 month trial of daily GlaucoCetin vs Placebo capsules.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived Quality of Life Improvement</measure>
    <time_frame>20 minute questionnaires during a 6 month period</time_frame>
    <description>Improvement in participants perceived vision-related quality of life (GQL-15, Glaucoma Symptom Scale (GSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Quality of Life Improvement measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)</measure>
    <time_frame>20 minute questionnaires during a 6 month period</time_frame>
    <description>Improvement in participants perceived vision-related quality of life ( National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25))</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>GlaucoCetin Peripheral Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Peripheral Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GlaucoCetin Central Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Central Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GlaucoCetin</intervention_name>
    <description>GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.</description>
    <arm_group_label>GlaucoCetin Central Group</arm_group_label>
    <arm_group_label>GlaucoCetin Peripheral Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.</description>
    <arm_group_label>Placebo Central Group</arm_group_label>
    <arm_group_label>Placebo Peripheral Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 40 to 80 years&#xD;
&#xD;
          -  Bilateral open angle glaucoma with reliable visual field defects (at least one eye&#xD;
             with mean deviation (MD) between -4.00 to -10.00 decibels (dB) on Humphrey Visual&#xD;
             Field 24-2.&#xD;
&#xD;
               -  Group 1 (Peripheral): meets 1 hodapp-parrish-anderson (HPA) criteria for defect&#xD;
                  (3 contiguous points depressed on the pattern standard deviation (PSD) p &lt;5%, one&#xD;
                  of which is depressed at p &lt;1% level), and does not meet below paracentral&#xD;
                  criteria for Group 2.&#xD;
&#xD;
               -  Group 2 (Central): at least 1 paracentral point repeatedly depressed at p&lt;1% on&#xD;
                  24-2. Also meets the HAP criteria outlined above.&#xD;
&#xD;
          -  Visual acuity 20/40 or better in each eye&#xD;
&#xD;
          -  Intraocular Pressure (IOP) controlled at 2 measurements &gt;3 months&#xD;
&#xD;
          -  Clear media&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known bleeding disorder&#xD;
&#xD;
          -  History of epilepsy or on anti-seizure medication&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Uncontrolled IOP&#xD;
&#xD;
          -  Eye pathology leading to inaccurate IOP measurement&#xD;
&#xD;
          -  Visually significant retinal pathology affecting vision in past or active (such as&#xD;
             diabetic retinopathy or age related macular degeneration)&#xD;
&#xD;
          -  Non-glaucomatous optic neuropathy&#xD;
&#xD;
          -  Visually significant cataract (worse then 2+ cataract, or what is determined visually&#xD;
             clinically significant by physician)&#xD;
&#xD;
          -  History of ocular trauma&#xD;
&#xD;
          -  Selective laser trabeculoplasty or laser procedure within past 3 months&#xD;
&#xD;
          -  Cataract surgery within past 3 months&#xD;
&#xD;
          -  Incisional glaucoma surgery within 6 months&#xD;
&#xD;
          -  Current use of nitroglycerin&#xD;
&#xD;
          -  Current use of antiplatelet therapy besides aspirin (such as clopidogrel) or&#xD;
             anticoagulation (such as warfarin)&#xD;
&#xD;
          -  Current use of systemic steroids or immunomodulating agents such as methotrexate.&#xD;
&#xD;
          -  Sensitivity or allergy to any ingredients in GlaucoCetin: Curcumin, L-Taurine,&#xD;
             N-Acetyl Cysteine, Niacinamide, Ginkgo Biloba, Lipoic Acid, Citicoline, Grape Seed&#xD;
             Extract, Green Tea Leaf Extract, Coenzyme Q10, Biotin, Natural Astaxanthin, flavonoid&#xD;
             complex containing Fisetin, Quercetin, and Luteolin&#xD;
&#xD;
          -  Recent change in systemic medications or vitamins&#xD;
&#xD;
          -  Use of Biotin, Ginkgo Biloba, Citicoline within past 3 months (or any other&#xD;
             Glaucocetin ingredients within 1 month)&#xD;
&#xD;
          -  Unreliable visual fields&#xD;
&#xD;
          -  Unwilling to take supplement or placebo for 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha N Kolomeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natasha N Kolomeyer, MD</last_name>
    <phone>215-928-3123</phone>
    <email>nkolomeyer@willseye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheryl Wizov, COA</last_name>
    <phone>12159283221</phone>
    <email>swizov@willseye.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wills Eye Hospital, Glaucoma Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Wizov</last_name>
      <phone>215-928-3221</phone>
      <email>swizov@willseye.org</email>
    </contact>
    <contact_backup>
      <last_name>Glaucoma Research Center</last_name>
      <phone>215-928-3123</phone>
    </contact_backup>
    <investigator>
      <last_name>Jonathan S Myers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Reza Razeghinejad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aakriti Shukla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Natasha Nayak Kolomeyer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>visual field loss</keyword>
  <keyword>vision enhancement</keyword>
  <keyword>GlaucoCetin</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

